|
2017 Journal Article EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemiaCharmsaz, S., Al-Ejeh, F., Yeadon, T. M., Miller, K. J., Smith, F. M., Stringer, B. W., Moore, A. S., Lee, F.-T., Cooper, L. T., Stylianou, C., Yarranton, G. T., Woronicz, J., Scott, A. M., Lackmann, M. and Boyd, A. W. (2017). EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia, 31 (8), 1779-1787. doi: 10.1038/leu.2016.371 |
|
2016 Journal Article Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumorsTorchia, Jonathon, Golbourn, Brian, Feng, Shengrui, Ho, King Ching, Sin-Chan, Patrick, Vasiljevic, Alexandre, Norman, Joseph D., Guilhamon, Paul, Garzia, Livia, Agamez, Natalia R., Lu, Mei, Chan, Tiffany S., Picard, Daniel, de Antonellis, Pasqualino, Khuong-Quang, Dong-Anh, Planello, Aline C., Zeller, Constanze, Barsyte-Lovejoy, Dalia, Lafay-Cousin, Lucie, Letourneau, Louis, Bourgey, Mathieu, Yu, Man, Gendoo, Deena M. A., Dzamba, Misko, Barszczyk, Mark, Medina, Tiago, Riemenschneider, Alexandra N., Morrissy, A. Sorana, Ra, Young-Shin ... Huang, Annie (2016). Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell, 30 (6), 891-908. doi: 10.1016/j.ccell.2016.11.003 |
|
2016 Journal Article A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemiaVormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K. E., Tall, J. R., Moore, A. S., Toguchi, M., Acton, G., Dyer, K., Schwab, C., Harrison, C. J., Grainger, J. D., Lancaster, D., Kearns, P., Hargrave, D. and Vormoor, J. (2016). A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood and Cancer, 64 (6) e26351, e26351. doi: 10.1002/pbc.26351 |
|
2016 Journal Article Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitorsSmith, Amanda M., Dun, Matthew D., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan, Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop and Verrills, Nicole M. (2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7 (30), 47465-47478. doi: 10.18632/oncotarget.10167 |
|
2016 Journal Article Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine gliomaNikbakht, Hamid, Panditharatna, Eshini, Mikael, Leonie G., Li, Rui, Gayden, Tenzin, Osmond, Matthew, Ho, Cheng-Ying, Kambhampati, Madhuri, Hwang, Eugene I., Faury, Damien, Siu, Alan, Papillon-Cavanagh, Simon, Bechet, Denise, Ligon, Keith L., Ellezam, Benjamin, Ingram, Wendy J., Stinson, Caedyn, Moore, Andrew S., Warren, Katherine E., Karamchandani, Jason, Packer, Roger J., Jabado, Nada, Majewski, Jacek and Nazarian, Javad (2016). Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 7 (1) 11185, 11185. doi: 10.1038/ncomms11185 |
|
2016 Journal Article Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysisThompson, Eric M., Hielscher, Thomas, Bouffet, Eric, Remke, Marc, Luu, Betty, Gururangan, Sridharan, McLendon, Roger E., Bigner, Darell D., Lipp, Eric S., Perreault, Sebastien, Cho, Yoon-Jae, Grant, Gerald, Kim, Seung-Ki, Lee, Ji Yeoun, Rao, Amulya A. Nageswara, Giannini, Caterina, Li, Kay Ja Wai, Ng, Ho-Keung, Yao, Yu, Kumabe, Toshihiro, Tominaga, Teiji, Grajkowska, Wieslawa A., Perek-Polnik, Marta, Low, David C. Y., Seow, Wan Tew, Chang, Kenneth T. E., Mora, Jaume, Pollack, Ian F., Hamilton, Ronald L. ... Taylor, Michael D. (2016). Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology, 17 (4), 484-495. doi: 10.1016/S1470-2045(15)00581-1 |
|
2016 Journal Article New brain tumor entities emerge from molecular classification of CNS-PNETsSturm, Dominik, Orr, Brent A., Toprak, Umut H., Hovestadt, Volker, Jones, David T. W., Capper, David, Sill, Martin, Buchhalter, Ivo, Northcott, Paul A., Leis, Irina, Ryzhova, Marina, Koelsche, Christian, Pfaff, Elke, Allen, Sariah J., Balasubramanian, Gnanaprakash, Worst, Babara C., Pajtler, Kristian W., Brabetz, Sebastian, Johann, Pascal D., Sahm, Felix, Reimand, Juri, Mackay, Alan, Carvalho, Diana M., Remke, Marc, Phillips, Joanna J., Perry, Arie, Cowdrey, Cynthia, Drissi, Rachid, Fouladi, Maryam ... Kool, Marcel (2016). New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell, 164 (5), 1060-1072. doi: 10.1016/j.cell.2016.01.015 |
|
2016 Conference Publication A pilot study to investigate the relationship between doxorubicin and doxorubicinol pharmacokinetics and cardiotoxicity in children and adolescents with cancer.Hennig, S., Kunarajah, K., Norris, R., Lobb, M., Charles, B., Pinkerton, R. and Moore, A. S. (2016). A pilot study to investigate the relationship between doxorubicin and doxorubicinol pharmacokinetics and cardiotoxicity in children and adolescents with cancer.. World Conference of Pharmacometrics, Brisbane / Brisbane Convention Centre, 21-24 August 2016. |
|
2015 Journal Article EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.Charmsaz, Sara, Beckett, Kirrilee, Smith, Fiona M., Bruedigam, Claudia, Moore, Andrew S., Al-Ejeh, Fares, Lane, Steven W. and Boyd, Andrew W. (2015). EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.. PLoS One, 10 (6) e0130692, e0130692-e0130692. doi: 10.1371/journal.pone.0130692 |
|
2015 Journal Article The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.Foresto, Steven A., Youlden, Danny R., Baader, Peter D., Hallahan, Andrew R., Aitken, Joanne F. and Moore, Andrew S. (2015). The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.. Pediatric Blood and Cancer, 62 (9), 1664-1666. doi: 10.1002/pbc.25517 |
|
2015 Journal Article Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemiaSmith, Amanda M., Little, Erica B., Zivanovic, Andjelija, Hong, Priscilla, Liu, Alfred K. S., Burow, Rachel, Stinson, Caedyn, Hallahan, Andrew R. and Moore, Andrew S. (2015). Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia. Leukemia Research, 39 (4), 435-444. doi: 10.1016/j.leukres.2015.01.005 |
|
2015 Conference Publication Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic SyndromeHahn, Christopher N., Babic, Milena, Schreiber, Andreas W., Kutyna, Monika M., Wee, L. Amilia, Brown, Anna L., Perugini, Michelle, Singhal, Deepak, Hiwase, Smita, Feng, Jinghua, Parker, Wendy T., Moore, Sarah, Bardy, Peter G., Saal, Russell, Marlton, Paula, Moore, Andrew S., Gonda, Thomas J., Leo, Paul, Branford, Susan, DAndrea, Richard J., Lewis, Ian D., Bik, Luen, Scott, Harnish S. and Hiwase, Devendra (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 5-8 December 2015. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood.V126.23.1644.1644 |
|
2014 Journal Article Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapyBruedigam, C., Bagger, F.O., Heidel, F.H., Paine, Kuhn C., Guignes, S., Song, A., Austin, R., Vu, T., Lee, E., Riyat, S., Moore, A.S., Lock, R.B., Bullinger, L., Hill, G.R., Armstrong, S.A., Williams, D.A. and Lane, S.W. (2014). Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell, 15 (6), 775-790. doi: 10.1016/j.stem.2014.11.010 |
|
2014 Journal Article Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemiaRoberts, K. G., Li, Y., Payne‑Turner, D., Harvey, R. C., Yang, Y.‑L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., Ma, J., Becksfort, J., Rusch, M., Chen, S.‑C., Easton, J., Cheng, J., Boggs, K., Santiago‑Morales, N., Iacobucci, I., Fulton, R. S., Wen, J., Valentine, M., Cheng, C., Paugh, S. W., Devidas, M., Chen, I.‑M., Reshmi, S., Smith, A., Hedlund, E. ... Mullighan, C. G. (2014). Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England Journal of Medicine, 371 (11), 1005-1015. doi: 10.1056/NEJMoa1403088 |
|
2014 Conference Publication Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)Bruedigam, Claudia, Bagger, Frederik Otzen, Heidel, Florian H., Kuhn, Catherine, Guignes, Solene, Song, Axia, Austin, Rebecca, Vu, Therese, Lee, Erwin M., Moore, Andrew S., Lock, Richard B., Bullinger, Lars, Hill, Geoff R. and Lane, Steven W. (2014). Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML). 56th Annual Meeting of the American Society of Hematology, San Francisco CA, United States, 06-09 December 2014. Washington, DC United States: American Society of Hematology. |
|
2013 Journal Article Vincristine sulfate liposomal injection for acute lymphoblastic leukemiaSoosay Raj, Trisha A., Smith, Amanda M. and Moore, Andrew S. (2013). Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. International Journal of Nanomedicine, 8 (1), 4361-4369. doi: 10.2147/IJN.S54657 |
|
2013 Journal Article BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupMoore, Andrew S., Alonzo, Todd A., Gerbing, Robert B., Lange, Beverly J., Heerema, Nyla A., Franklin, Janet, Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S. and Meshinchi, Soheil (2013). BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood and Cancer, 61 (4), 647-652. doi: 10.1002/pbc.24822 |
|
2013 Journal Article Novel therapies for children with acute myeloid leukaemiaMoore, A. S., Kearns, P. R., Knapper, S., Pearson, A. D. J. and Zwaan, C. M. (2013). Novel therapies for children with acute myeloid leukaemia. Leukemia, 27 (7), 1451-1460. doi: 10.1038/leu.2013.106 |
|
2012 Journal Article Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaBavetsias, Vassilios, Crumpler, Simon, Sun, Chongbo, Avery, Sian, Atrash, Butrus, Faisal, Amir, Moore, Andrew S., Kosmopoulou, Magda, Brown, Nathan, Sheldrake, Peter W., Bush, Katherine, Henley, Alan, Box, Gary, Valenti, Melanie, Brandon, Alexis de Haven, Raynaud, Florence I., Workman, Paul, Eccles, Suzanne A., Bayliss, Richard, Linardopoulos, Spiros and Blagg, Julian (2012). Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 55 (20), 8721-8734. doi: 10.1021/jm300952s |
|
2012 Journal Article Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patternsMoore, A. S., Faisal, A., Gonzalez de Castro, D., Bavetsias, V., Sun, C., Atrash, B., Valenti, M., de Haven Brandon, A., Avery, S., Mair, D., Mirabella, F., Swansbury, J., Pearson, A. D. J., Workman, P., Blagg, J., Raynaud, F. I., Eccles, S. A. and Linardopoulos, S. (2012). Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns. Leukemia, 26 (7), 1462-1470. doi: 10.1038/leu.2012.52 |
